Ian Douglas, PhD, BSc, professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, who was also not involved in the study, pointed out: The time at which someone starts a treatment for obesity can itself be correlated with mental health difficulties, and the effects of the medication on weight, whether this is a dramatic reduction in weight, or a disappointing lack of weight reduction, can also trigger changes in mental health. If we want to know whether GLP-1 agonists cause changes in mental health status, either through their direct pharmacological action or indirectly through their action on weight, we ideally need studies that compare people treated with GLP-1 agonists with similar people not receiving them to see if there are differences in their risk of mental health outcomes. Ian Douglas, PhD, BSc Of the NIH study, Douglas said, I wouldnt go so far as to say GLP-1 agonists prevent mental health problems based on these findings, but the results are certainly not consistent with a harm. Douglas questioned the methodology used in the new study, saying that individual spontaneous reports of suspected adverse drug reactions [] such as those used in the new study are not an appropriate resource in which to test this hypothesis about GLP-1 agonists. Ali expressed a similar concern
A green chemical route for synthesis of graphene supported palladium nanoparticles: A highly active and recyclable catalyst for reduction of nitrobenzene
He will establish a treatment regimen consistent with your body, diet and lifestyle
A.MartinsF
